Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03832738 · ClinicalTrials.gov registry record · Phase 2

Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis

A Phase 2 study of Psoriasis and Plaque Psoriasis, sponsored by Akros Pharma.

Completed
Registry status
Phase 2
Development phase
152
Enrollment target
20
Study locations

NCT03832738 is a Phase 2 study of Psoriasis and Plaque Psoriasis that has completed, run by Akros Pharma. The registered enrollment target is 152 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03832738, a Phase 2 study of Psoriasis and Plaque Psoriasis, has completed, sponsored by Akros Pharma.

COMPLETED
Registry status
Phase 2
Development phase
152 participants
Enrollment target
20
Study locations

Study Summary

Study to evaluate the efficacy and safety of JTE-451 administered for 16 weeks in subjects with moderate to severe plaque psoriasis.

Conditions Studied

Psoriasis Plaque Psoriasis Skin Diseases

Interventions

  • DRUG Placebo Tablets
  • DRUG JTE-451 Tablets

Study Locations (20)

Other

  • Szpital Uniwersytecki nr 1 im. Dr. A. Jurasza w Bydgoszczy, Klinika Dermatologii, Chorob Prenoszonych Droga Plciowa - Bydgoszcz
  • Copernicus Podmiot Leczniczy Sp. z o.o., Oddzial Dermatologii - Gdansk
  • Prywatny Gabinet Dermatologiczny Elzbieta Klujszo - Kielce
  • Centrum Nowoczesnych Terapii "Dobry Lekarz" Spolka z orgraniczona odpowiedzialnoscia - Krakow
  • Centrum Terapii Wspolczesnej J.M. Jasnorzewska Spolka Komandytowo-Akeyjna - Lodz
  • ETG Lodz - Lodz
  • Dermoklinika - Centrum Medyczne s.c., M. Kierstan, J. Narbutt, A. Lesiak - Lodz
  • ETG Lublin - Lublin

Ontario

  • SimcoDerm Medical and Surgical Dermatology Center - Barrie
  • SKiN Health - Cobourg
  • Research Toronto - Toronto
  • K. Papp Clinical Research - Waterloo

California

  • Clinical Science Institute - Santa Monica
  • Advanced Dermatology and Skin Cancer Specialists - Temecula

Indiana

  • Dawes Fretzin Clinical Research Group, LLC - Indianapolis

Oklahoma

  • Central Sooner Research - Norman

Rhode Island

  • Rhode Island Hospital - Providence

South Dakota

  • Health Concepts - Rapid City

Manitoba

  • Wiseman Dermatology Research Inc. - Winnipeg

Trial Details

FieldValue
Enrollment Target 152 participants
Start Date 2019-01-17
Est. Completion 2020-03-13
Phase Phase 2

Sponsor

Akros Pharma

18 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03832738

The ClinicalTrials.gov registry entry for NCT03832738 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (69% lower). The listed sponsor is Akros Pharma, which has 18 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo Tablets is the first listed.

NCT03832738 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Ontario, California.

Frequently Asked Questions

What is clinical trial NCT03832738 about?

NCT03832738 is a clinical study titled "Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis". Study to evaluate the efficacy and safety of JTE-451 administered for 16 weeks in subjects with moderate to severe plaque psoriasis.

What is the current status of trial NCT03832738?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 152 participants. The study started on 2019-01-17. Estimated completion is 2020-03-13.

What conditions does trial NCT03832738 study?

This clinical trial studies the following conditions: Psoriasis, Plaque Psoriasis, Skin Diseases.

What interventions are being tested in trial NCT03832738?

The interventions under investigation include: Placebo Tablets (DRUG), JTE-451 Tablets (DRUG).

Who is sponsoring clinical trial NCT03832738?

This trial is sponsored by Akros Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03832738 being conducted?

This trial has 20 study locations across California, Indiana, Oklahoma, Rhode Island, South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Psoriasis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Psoriasis

All registered trials for this condition

Plaque Psoriasis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.